Knight Therapeutics (TSE:GUD) Earns “Outperform” Rating from Raymond James
Raymond James reiterated their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a research report sent to investors on Thursday morning, BayStreet.CA reports. Raymond James currently has a C$10.25 price target on the stock.
Shares of GUD stock opened at C$7.55 on Thursday. The company has a 50 day moving average of C$7.57. Knight Therapeutics has a twelve month low of C$7.10 and a twelve month high of C$8.76. The stock has a market cap of $1.08 billion and a P/E ratio of 48.40. The company has a quick ratio of 31.73, a current ratio of 32.29 and a debt-to-equity ratio of 0.10.
Knight Therapeutics (TSE:GUD) last announced its earnings results on Thursday, May 9th. The company reported C$0.04 earnings per share for the quarter, beating the consensus estimate of C$0.03 by C$0.01. The company had revenue of C$2.96 million during the quarter, compared to analysts’ expectations of C$3.06 million. Research analysts expect that Knight Therapeutics will post 0.15 EPS for the current year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Featured Story: What are Bollinger Bands?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.